Peter Carney - Mustang Bio Controller Officer
| MBIO Stock | USD 0.19 0 2.11% |
Executive
Peter Carney is Controller Officer of Mustang Bio
| Age | 37 |
| Address | 377 Plantation Street, Worcester, MA, United States, 01605 |
| Phone | 781 652 4500 |
| Web | https://www.mustangbio.com |
Mustang Bio Management Efficiency
The company has return on total asset (ROA) of (0.9652) % which means that it has lost $0.9652 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.9131) %, meaning that it created substantial loss on money invested by shareholders. Mustang Bio's management efficiency ratios could be used to measure how well Mustang Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of December 2024, Return On Tangible Assets is likely to grow to -2.76. In addition to that, Return On Capital Employed is likely to grow to -20.32. At this time, Mustang Bio's Net Tangible Assets are very stable compared to the past year. As of the 11th of December 2024, Non Current Assets Total is likely to grow to about 8.8 M, while Total Assets are likely to drop about 16.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Roger BSc | Aptose Biosciences | N/A | |
| Jeffrey Arcara | Corvus Pharmaceuticals | N/A | |
| Dr MPH | Dermata Therapeutics | 59 | |
| MPH MD | Salarius Pharmaceuticals | N/A | |
| Cynthia MD | Leap Therapeutics | 54 | |
| Robyn Hunter | Fortress Biotech Pref | 61 | |
| Mary Sandin | Affimed NV | N/A | |
| John Lunger | Adaptimmune Therapeutics Plc | 54 | |
| Maria MBA | Dermata Therapeutics | 73 | |
| MD BA | Adaptimmune Therapeutics Plc | 60 | |
| Marc Wiles | Aptose Biosciences | N/A | |
| Pablo MD | Kodiak Sciences | N/A | |
| Lee Stern | Achilles Therapeutics PLC | N/A | |
| Douglas MBA | Unicycive Therapeutics | 62 | |
| MS MD | Aditxt Inc | N/A | |
| Arndt MD | Affimed NV | 58 | |
| Sean Proehl | Dermata Therapeutics | N/A | |
| James MD | Corvus Pharmaceuticals | N/A | |
| BethAnne Lang | Akari Therapeutics PLC | N/A | |
| Michael Wolf | Affimed NV | 57 | |
| Dolly Tyan | Aditxt Inc | N/A | |
Management Performance
| Return On Equity | -11.91 | ||||
| Return On Asset | -0.97 |
Mustang Bio Leadership Team
Elected by the shareholders, the Mustang Bio's board of directors comprises two types of representatives: Mustang Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mustang. The board's role is to monitor Mustang Bio's management team and ensure that shareholders' interests are well served. Mustang Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mustang Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eliot CPA, Interim Officer | ||
| Richard MS, Head Development | ||
| Manuel MD, CEO, President | ||
| Matthew JD, VP Counsel | ||
| Bruce MD, Senior Development | ||
| Lynn MS, VP Affairs | ||
| Peter Carney, Controller Officer | ||
| James Murphy, Interim Officer | ||
| MS MBA, VP Leadership | ||
| Robyn Hunter, Co Sec | ||
| Scott MBA, Ex Management | ||
| Knut Niss, Chief Officer | ||
| Greg MS, Chief Officer | ||
| Michael Esq, Executive Chairman | ||
| Debra SPHR, Senior Resources |
Mustang Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mustang Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.91 | ||||
| Return On Asset | -0.97 | ||||
| Current Valuation | 6.53 M | ||||
| Shares Outstanding | 46.93 M | ||||
| Shares Owned By Insiders | 7.48 % | ||||
| Shares Owned By Institutions | 5.72 % | ||||
| Number Of Shares Shorted | 424.91 K | ||||
| Price To Earning | (11.40) X | ||||
| Price To Book | 31.75 X | ||||
| EBITDA | (48.06 M) |
Pair Trading with Mustang Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mustang Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mustang Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Mustang Stock
Moving against Mustang Stock
| 0.58 | DYAI | Dyadic International | PairCorr |
| 0.51 | ESPR | Esperion Therapeutics | PairCorr |
| 0.47 | BMY | Bristol Myers Squibb | PairCorr |
| 0.36 | DNA | Ginkgo Bioworks Holdings | PairCorr |
The ability to find closely correlated positions to Mustang Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mustang Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mustang Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mustang Bio to buy it.
The correlation of Mustang Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mustang Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mustang Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mustang Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mustang Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Mustang Stock, please use our How to Invest in Mustang Bio guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mustang Bio. If investors know Mustang will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mustang Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.33) | Revenue Per Share (0) | Return On Assets (0.97) | Return On Equity (11.91) |
The market value of Mustang Bio is measured differently than its book value, which is the value of Mustang that is recorded on the company's balance sheet. Investors also form their own opinion of Mustang Bio's value that differs from its market value or its book value, called intrinsic value, which is Mustang Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mustang Bio's market value can be influenced by many factors that don't directly affect Mustang Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mustang Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mustang Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mustang Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.